Abu Dhabi, United Arab Emirates, 18 December 2025: Burjeel Holdings PLC ("Burjeel" or "the Group"), a leading super-specialty healthcare services provider in MENA listed on the Abu Dhabi Securities Exchange (SYMBOL: BURJEEL; ISIN: AEE01119B224), today announced that its Board of Directors has approved the appointment of Dr. Shamsheer Vayalil as Chief Executive Officer, in addition to his current role as Founder and Chairman of the Board, subject to obtaining the required shareholder and regulatory approvals.

The Board's decision reflects its assessment that Burjeel Holdings has reached a stage of scale and maturity where alignment between strategic leadership and operational oversight will support clinical excellence, disciplined growth, and long-term value creation across the Group.

Burjeel's high-quality healthcare asset portfolio provides a strong and scalable platform for growth and value creation. Through disciplined capital allocation and a clear strategic agenda, my focus will be on strengthening performance across the portfolio, supporting sustainable growth, and delivering long-term value for all our stakeholders.

The Board also approved the necessary steps to formalize and implement the appointment, including seeking shareholder approval through a General Assembly Meeting of shareholders, as required. The Board further determined that this leadership evolution should be accompanied by strengthened independent oversight, including through the Board and a Governance Committee, to ensure robust accountability and protection of the interests of all shareholders.

The Board approved the conclusion of Mr. John Sunil's role as Chief Executive Officer and Mr. Safeer Ahamed's role as Co-Chief Executive Officer, and expressed its appreciation for their leadership and contributions to the development and performance of Burjeel Holdings.

Burjeel Holdings will continue to execute its strategy focused on leadership in complex and specialized care, anchored by Abu Dhabi as a regional referral hub, while pursuing disciplined expansion in the UAE and Saudi Arabia and capital-light operating partnerships. The Group remains focused on improving utilization across its existing asset base, supported by continued investment in clinical talent, digital and AI-enabled care delivery, and research, with a consistent emphasis on quality outcomes and sustainable growth.

The Board has also approved the budget for the financial year 2026, the highest annual budget to date.

Further details regarding the General Assembly Meeting of shareholders and the related shareholder approvals will be communicated in due course in accordance with applicable regulations.

Investor Conference Call

Burjeel Holdings leadership will host an investor conference call to discuss the Board-approved CEO appointment.

Date: Friday, 19 December 2025

Time: 3:00 pm Gulf Standard Time (GST)

Please find the details of the conference call below.

Webcast Link

United Arab Emirates: 800 0320690

United Kingdom: +44 203 984 9844

United States: +1 718 866 4614

Global Dial-In Numbers

Access Code: 305568

About Dr. Shamsheer Vayalil

Dr. Shamsheer Vayalil founded Burjeel Holdings in 2007 and has served as Chairman of the Board since its establishment. Burjeel Holdings has grown into a leading healthcare group with operations across the United Arab Emirates, Oman, and Saudi Arabia, with a focus on complex and specialized care. Dr. Shamsheer has also been involved in the establishment and development of healthcare and education businesses in the Middle East and India.

About Burjeel Holdings

Founded in 2007, Burjeel Holdings is a leading super-specialty healthcare services provider in the UAE and Oman, and it operates a growing specialized healthcare segment in Saudi Arabia. The Group operates an integrated and multi-brand healthcare ecosystem across primary, secondary, tertiary, and quaternary medical care, ensuring complex care delivery to patients across all socioeconomic groups. Its network comprises 112 assets across the UAE, Oman, and Saudi Arabia, including 20 hospitals, 37 medical centers, 30 physiotherapy and wellness centers, 15 pharmacies, and 10 other allied services. Burjeel Holdings' brands include Burjeel, Medeor, LLH, Lifecare, PhysioTherabia and Tajmeel.

Contacts

Investor Relations:

Sergei Levitskii

Director of Investor Relations

ir@burjeelholdings.com

M: +971 50 380 2383

Media:

M. Unnikrishnan

Corporate Communications Officer

krish@burjeelholdings.com

M: +971 50 427 5895

Burjeel Holdings Announces Board-Approved CEO Appointment